HLS Therapeutics Inc (74D) Stock Price & Analysis
74D Stock Chart & Stats
- Day’s Range
- EUR 2.72 - EUR 2.78
- 52-Week Range
- EUR 2.04 - EUR 3.26
- Previous Close
- EUR 2.76
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- EUR 89.09M
- Enterprise Value
- EUR 177.89M
- Total Cash (Recent Filing)
- EUR 13.71M
- Total Debt (Recent Filing)
- EUR 41.84M
- Price to Earnings (P/E)
- ―
- Beta
- 0.04
- Next Earnings
- Nov 12, 2026 (Est.)
- EPS Estimate
- -0.06
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation
Consistently positive operating and free cash flow gives HLS internal funding capacity while accounting earnings remain negative. This supports debt reduction, product investment, and operating resilience, making the business less dependent on external financing over the next several quarters.
Cardiovascular Portfolio Momentum
Rapid cardiovascular growth provides a durable expansion engine beyond the existing portfolio. Vascepa is delivering double-digit sales and unit growth, while Nilemdo is gaining prescriptions and payer access, creating a broader base for revenue and margin growth.
Improving Balance Sheet
Meaningful deleveraging improves financial flexibility and should reduce interest burdens, allowing more cash to support commercialization and growth. Lower debt also strengthens HLS's ability to manage product launches and absorb operating volatility over the medium term.
Bears Say
Persistent Accounting Losses
Persistent net losses and negative return on equity show that HLS has not yet converted its healthy EBITDA and cash generation into sustainable bottom-line profitability. This limits earnings quality and could constrain capital allocation if losses continue across coming reporting periods.
U.S. Clozaril Pressure
Declining U.S. Clozaril revenue and an expectation of flat sales indicate that an established product is unlikely to provide near-term growth support. Continued weakness places more importance on successful cardiovascular launches to offset pressure in the existing portfolio.
Margin Pressure From Launch Costs
Nilemdo commercialization is currently consuming investment before its revenue scale fully offsets higher expenses. The resulting EBITDA decline demonstrates near-term margin pressure, and sustained spending could delay the point at which portfolio growth translates into stronger overall profitability.
HLS Therapeutics Inc News
74D FAQ
What was HLS Therapeutics Inc’s price range in the past 12 months?
What is HLS Therapeutics Inc’s market cap?
When is HLS Therapeutics Inc’s upcoming earnings report date?
How were HLS Therapeutics Inc’s earnings last quarter?
Is HLS Therapeutics Inc overvalued?
Does HLS Therapeutics Inc pay dividends?
What is HLS Therapeutics Inc’s EPS estimate?
How many shares outstanding does HLS Therapeutics Inc have?
What happened to HLS Therapeutics Inc’s price movement after its last earnings report?
Which hedge fund is a major shareholder of HLS Therapeutics Inc?
What is the TipRanks Smart Score and how is it calculated?
HLS Therapeutics Inc Stock Smart Score
Company Description
HLS Therapeutics Inc
HLS Therapeutics Inc. operates as a specialized pharmaceutical firm, concentrating on the acquisition and commercialization of medicinal products, primarily within the niche central nervous system (CNS) and cardiovascular (CV) sectors. Its reach extends across Canada, the United States, and international markets. The company's core product lineup includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsule formulation; and PERSERIS, an injectable risperidone product for treating schizophrenia. Additionally, HLS offers MyCare psychiatry laboratory assays and MyCare Insite tests for point-of-care therapeutic drug-level monitoring. Furthermore, the company possesses U.S. marketing privileges for Absorica, a commercial-stage dermatology solution, and Canadian rights for Trinomia, a cardiovascular therapeutic. It also manages a portfolio of royalty interests from four distinct healthcare products. Founded in 2018, HLS Therapeutics Inc. is based in Etobicoke, Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Craig Stuart Millian
- Employees
- 85
- Website
- www.hlstherapeutics.com
- Address
- 10 Carlson Court, Etobicoke, ON, M9W 6L2, CA
HLS Therapeutics Inc (74D) Earnings & Revenues
74D Earnings Call
Earnings Call SentimentPositive
The call conveyed an overall constructive outlook: the company demonstrated clear progress deleveraging the balance sheet, improving cash generation, and achieving strong early momentum in its cardiovascular franchise (notably Vascepa and Nilemdo) with meaningful payer wins and upcoming regulatory catalysts (NEXLIZET). Near-term profitability was pressured by launch investments (Nilemdo) and higher cost of sales and operating expenses, and U.S. Clozaril showed declines, but management reaffirmed 2026 guidance and expects margin improvement in the second half as revenue ramps. Net balance favors positive developments driven by durable CV growth and a stronger balance sheet, despite some short-term operational and margin headwinds.
View all DE:74D earnings summaries74D Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 1 | 6 |
| Technical Analysis | 3 | 1 | 6 |
| Moving Averages | 12 | 0 | 0 |